Bluebird Bio will sell itself to private equity firms Carlyle and SK Capital for about $30 million. Bluebird makes three gene ...
Lexeo Therapeutics Inc.’s phase I/II data – characterized by Oppenheimer analyst Leland Gershell as “heroic” – this week with gene therapy LX-2020 in PKP2-associated arrhythmogenic cardiomyopathy ...
A new CRISPR breakthrough shows scientists can turn genes back on without cutting DNA, by removing chemical tags that act like molecular anchors. The work confirms these tags actively silence genes, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results